Cambridge Investment Research Advisors, Inc. Editas Medicine, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 85,716 shares of EDIT stock, worth $253,719. This represents 0.0% of its overall portfolio holdings.
Number of Shares
85,716
Previous 86,347
0.73%
Holding current value
$253,719
Previous $110,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding EDIT
# of Institutions
221Shares Held
48.5MCall Options Held
436KPut Options Held
324K-
Black Rock Inc. New York, NY7.78MShares$23 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.47MShares$22.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.66MShares$7.87 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL2.6MShares$7.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.94MShares$5.75 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $203M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...